Table 1. Hit rate for each member of the Nek family based upon screening data from large published screening sets with FLT3 values for comparison.

Compound set	PKIS a	PKIS2 b	BMS c	RBC d	Ambit e	GSK f	Millipore g
No. of cmpds	368	645	21 851	178	72	577	158
Nek1	0.011	0.051	0.001	0.051	0.014	—	—
Nek2	0.005	0.057	0.003	0.006	0.056	0.059	0.006
Nek3	—	0.031	—	0.006	0.014	—	0
Nek4	—	0.012	—	0.039	0.014	—	—
Nek5	—	0.065	0.0286	—	0.014	—	—
Nek6	0	0.023	0.017	0	0.042	0.031	0
Nek7	0	0.035	0.0315	0	0.042	0.035	0
Nek8	—	—	—	—	—	—	—
Nek9	0.033	0.051	0.009	0.028	0.042	0.016	—
Nek10	—	0.059	—	—	—	—	—
Nek11	—	0.031	—	0.011	0.042	—	0.095
FLT3	0.14	0.23	0.15	0.41	0.036	0.14	0.3

^aValues for PKIS calculated by the number of compounds that inhibited each Nek by ≥50% divided by the total number of compounds screened (Elkins et al., 2016).

^bValues for PKIS2 calculated by the number of compounds that inhibited each Nek ≥50% divided by the total number of compounds screened (Drewry et al., 2017).

^cValues from Bristol-Myers Squibb screening data (hit rate calculated based on <13% of control) (Posy et al., 2011).

^dValues from Reaction Biology Corporation data (Anastassiasdis et al., 2011).

^eValues calculated from reported ambit K_d values – number of compounds that inhibit each Nek ≥500 nM divided by the total number of compounds (Davis et al., 2011).

^fValues from GlaxoSmithKline screening taken from Nc ≤ 1 (Bamborough et al., 2008).

^gValues calculated using EMD millipore screening data. Number of compounds that inhibit each Nek ≥50% divided by total number of compounds screened (Gao et al., 2013).